Sen. Shelley Moore Capito Sells Abbott Laboratories (NYSE:ABT) Shares

Senator Shelley Moore Capito (R-West Virginia) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on March 06th, the Senator disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on February 24th.

Senator Shelley Moore Capito also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Accenture (NYSE:ACN) on 2/24/2025.
• Sold $1,001 – $15,000 in shares of Comcast (NASDAQ:CMCSA) on 2/24/2025.
• Sold $1,001 – $15,000 in shares of Apple (NASDAQ:AAPL) on 2/5/2025.
• Purchased $1,001 – $15,000 in shares of Constellation Energy (NASDAQ:CEG) on 2/4/2025.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 2/4/2025.
• Sold $1,001 – $15,000 in shares of W.W. Grainger (NYSE:GWW) on 1/17/2025.
• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/17/2025.
• Sold $1,001 – $15,000 in shares of BlackRock (NYSE:BLK) on 1/17/2025.
• Sold $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 1/17/2025.
• Sold $1,001 – $15,000 in shares of Phillips 66 (NYSE:PSX) on 1/17/2025.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $134.90 on Friday. The firm has a market cap of $233.97 billion, a price-to-earnings ratio of 17.63, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75. The stock has a fifty day simple moving average of $124.90 and a two-hundred day simple moving average of $118.53. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting the consensus estimate of $1.34. The company had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.19 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a $0.59 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.75%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 30.85%.

Hedge Funds Weigh In On Abbott Laboratories

Several institutional investors and hedge funds have recently bought and sold shares of ABT. Redwood Park Advisors LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $25,000. Noble Wealth Management PBC bought a new stake in shares of Abbott Laboratories in the fourth quarter worth about $26,000. NewSquare Capital LLC raised its position in Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock valued at $27,000 after purchasing an additional 105 shares during the last quarter. WealthTrak Capital Management LLC purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $28,000. Finally, Rialto Wealth Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $29,000. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ABT has been the subject of a number of recent research reports. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, January 23rd. The Goldman Sachs Group lifted their price target on Abbott Laboratories from $138.00 to $154.00 and gave the company a “buy” rating in a research report on Tuesday. Royal Bank of Canada reissued an “outperform” rating and set a $135.00 price objective on shares of Abbott Laboratories in a report on Tuesday, January 21st. Argus raised Abbott Laboratories to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, StockNews.com downgraded shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $137.19.

Insider Activity at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $128.50, for a total value of $3,054,573.50. Following the completion of the transaction, the executive vice president now directly owns 125,697 shares of the company’s stock, valued at $16,152,064.50. This represents a 15.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Eric Shroff sold 562 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the sale, the senior vice president now owns 31,970 shares in the company, valued at $4,417,294.90. This represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 25,282 shares of company stock worth $3,263,348 over the last quarter. 1.10% of the stock is owned by corporate insiders.

About Senator Capito

Shelley Moore Capito (Republican Party) is a member of the U.S. Senate from West Virginia. She assumed office on January 3, 2015. Her current term ends on January 3, 2027. Capito (Republican Party) ran for re-election to the U.S. Senate to represent West Virginia. She won in the general election on November 3, 2020. Capito was first elected to the Senate in 2014, becoming the first female U.S. Senator in the state’s history. Prior to serving in the Senate, Capito was a member of the West Virginia House of Representatives from 1997 to 2001 and a member of the United States House of Representatives from 2001 to 2015. At the start of the 116th Congress, Capito was a member of the U.S. Senate committees on Appropriations, Commerce, Science, and Transportation, Environment and Public Works, and Rules and Administration. As of a 2014 analysis of multiple outside rankings, Capito is a more moderate right of center Republican Party vote. As a result, she may break with the Republican Party line more than her fellow members. Capito earned her bachelor’s degree from Duke University. After earning her M.Ed. from the University of Virginia, Capito was a college counselor and then director of an educational information center. She was the only Republican in the West Virginia congressional delegation until the 2010 elections and is the first Republican woman elected to Congress from West Virginia. Capito is a former chairwoman of the Congressional Caucus for Women’s Issues, as well as a member of the Congressional Arts Caucus. After an explosion responsible for the death of 29 coal workers, Capito founded the Congressional Coal Caucus. Prior to her election to the U.S. House, Capito served in the West Virginia House of Delegates.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.